[1]
Y. Toi, “Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study”, Sarcoidosis vasculitis and diffuse lung disease, vol. 36, no. 1, pp. 74-78, Mar. 2019.